Evotec entered into a strategic collaboration and license agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration focuses on the development of first-in-class targeted immune-based therapies for oncology, which will ultimately be commercialized by Janssen. The agreement was facilitated by Johnson & Johnson Innovation.
Researchers at the University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate designed to stimulate immune-mediated eradication of tumors.
